P/E at 31.09 vs Industry's 36.69: What the Data Shows for Dr Reddys Laboratories Ltd

Valuation Picture: Discount Amid Sector Premiums

The current P/E of 31.09 for Dr Reddys Laboratories Ltd stands below the industry average of 36.69, signalling a valuation discount of roughly 15%. This gap suggests the market is pricing in either a relative earnings risk or a subdued growth outlook compared to peers. In a sector where many large caps command premiums due to robust pipelines and global reach, this discount may reflect concerns over recent operational challenges or competitive pressures. However, it also implies that the stock is not trading at an excessive premium, which can be a factor for investors analysing valuation versus performance metrics — previously rated Hold, what is Dr Reddys Laboratories Ltd’s current rating?

Performance Across Timeframes: Divergent Momentum

Examining returns over multiple periods reveals a complex momentum profile. Over the past year, Dr Reddys Laboratories Ltd has declined by 4.17%, outperforming the Sensex’s 10.91% fall. This relative resilience suggests some defensive qualities or company-specific strengths. Yet, the three-month return of -12.99% is markedly weaker than the Sensex’s -6.96%, indicating recent headwinds. The one-month performance bucks this trend with a 3.64% gain, contrasting with the Sensex’s 5.44% loss. This short-term bounce partially reverses the prior quarterly weakness — is this a genuine recovery or a relief rally that will fade at the 50 DMA? — the moving average configuration provides the clearest answer.

Moving Average Configuration: Mixed Technical Signals

The technical setup for Dr Reddys Laboratories Ltd is characterised by a nuanced moving average (MA) picture. The stock price currently sits above the 20-day and 50-day moving averages, signalling some short to medium-term strength. However, it remains below the 5-day, 100-day, and 200-day moving averages, indicating that the longer-term trend is still under pressure. This configuration often points to a recent bounce within a broader downtrend, suggesting caution for momentum traders. The stock has also recorded three consecutive days of decline, losing 5.44% in that span, which tempers the optimism from the short-term MA crosses.

Relative Performance vs Sensex: Defensive Over Longer Term

Over the year-to-date period, Dr Reddys Laboratories Ltd has declined by 5.90%, outperforming the Sensex’s sharper fall of 15.10%. This relative outperformance suggests some defensive qualities amid broader market weakness. However, the stock’s 1-week and 1-day performances have lagged the Sensex, with returns of -2.17% versus -0.58% and -0.34% versus 0.61% respectively, indicating short-term pressures. The longer-term returns over three and five years show mixed results: a 10.58% gain over three years slightly outpaces the Sensex’s 10.24%, while the five-year return of 18.82% trails the Sensex’s 21.10%. The 10-year return of 91.60% is significantly below the Sensex’s 156.37%, reflecting a more modest long-term growth trajectory.

Sector Performance Context: Pharmaceuticals & Biotechnology

The Pharmaceuticals & Biotechnology sector has experienced a mixed performance landscape recently. While some companies have benefited from innovation and export growth, others face pricing pressures and regulatory challenges. Within this context, Dr Reddys Laboratories Ltd’s valuation discount and recent performance volatility align with sector-wide uncertainties. The sector’s average P/E of 36.69 reflects investor willingness to pay a premium for growth and stability, which Dr Reddys Laboratories Ltd currently trades below, highlighting a divergence in market perception.

Rating Reassessment: Previously Hold, Now Updated

MarketsMOJO had previously rated Dr Reddys Laboratories Ltd as Hold. The rating was reassessed on 13 Jul 2026, reflecting the evolving valuation and performance data. The current Mojo Score stands at 36.0, with a Mojo Grade of Sell. This shift underscores the tension between the stock’s valuation discount and its recent underperformance, particularly over the three-month horizon. The reassessment invites investors to consider whether the current rating aligns with their portfolio objectives — should investors in Dr Reddys Laboratories Ltd hold, buy more, or reconsider?

Conclusion: A Complex Valuation and Momentum Profile

The data for Dr Reddys Laboratories Ltd reveals a stock trading at a meaningful discount to its sector P/E, coupled with a mixed performance record. While the one-year and year-to-date returns show relative resilience, the recent three-month decline and technical indicators suggest caution. The moving average configuration highlights a short-term bounce within a longer-term downtrend, and the stock’s recent consecutive losses add to the uncertainty. The sector’s overall performance and premium valuation backdrop further contextualise the stock’s current standing. Investors analysing this data may find the reassessment from Hold to Sell by MarketsMOJO a critical factor in their decision-making process — what is the current rating for Dr Reddys Laboratories Ltd?

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today